Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

2

Revenue 2014

Sovaldi/Harvoni

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Sovaldi/Harvoni was produced by Gilead Sciences.

Torrid times at Gilead lead to calls for a major M&A deal

Torrid times at Gilead lead to calls for a major M&A deal

Sales of its hepatitis drugs Sovaldi, Harvoni and Epclusa were down $1.5bn in the same period of 2015 to $3.3bn, with overall revenues down almost 10% to $7.5bn

Gilead’s hepatitis C sales start to slide – the question is how quickly?

Gilead’s hepatitis C sales start to slide – the question is how quickly? The US pharma company has reaped the benefits of stellar sales for its directly-acting HCV therapies since it first launched Sovaldi (sofosbuvir) in 2013 and two-drug follow-up Harvoni

European pharma ‘to grow 3.2% per year by 2022’

European pharma ‘to grow 3.2% per year by 2022’ In hepatitis C, Gilead's Sovaldi (2015: 1.443 bn; 2022: 609m) and its follow-up therapy Harvoni (2015: 2 bn; 2022: 887m) million) will struggle due to price pressure and

FDA approves Gilead's 'universal' hep C combination Epclusa

FDA approves Gilead's 'universal' hep C combination Epclusa Epclusa joins Sovaldi and Harvoni (sofosbuvir/ledipasvir), a product specifically indicated for patients with hepatitis C virus genotype 1 infection, in Gilead's hep C portfolio. ... Sovaldi and Harvoni brought in sales of $5.3bn and $13.9bn respectively

Gilead must pay just $200m for hep C patents, says jury

Gilead must pay just $200m for hep C patents, says jury Merck &Co awarded a 4% royalty rate on sales of Sovaldi and Harvoni. ... Merck had been pushing for a 10% royalty rate on the $20.7bn Gilead had made from sales of two sofosbuvir-based drugs - Sovaldi and Harvoni - between 2013 and 2015, after

Result pages: 1 | 2 | 3 ()

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health offers a unique breadth and depth of experience, across everything from early stage product commercialisation, strategy and research,...

Latest intelligence

Where is health behaviour change heading?
Cures rely on patient adherence to succeed, and health behaviour change in any non-compliant patient is essential, this post explores where health behaviour change is heading....
Pharma email marketing: Your top 12 tips
Used correctly, email can be one of the most effective and cost-efficient channels for a pharma company to use. To help you get the most from it, we've rounded up...
arrow
Patently unclear?
The challenge of protecting biotech innovations...

Infographics